Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)

NCT04716231 is registered in ClinicalTrials.gov with Vera Therapeutics, Inc. as lead sponsor.

NCT NCT04716231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04716231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)
Lead sponsor
Vera Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 29, 2023
Completion date
July 31, 2028
Enrollment
428 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

berger disease, iga nephropathy